Navigation

Renal cell carcinoma (advanced) - axitinib [ID518]

Axitinib for the treatment of advanced renal cell carcinoma after failure of prior systemic treatment

Status: In development
Expected date of issue: June 2014
Referral date: February 2012
Process: STA
Notes:

Scoped as part of Batch 21

Topic area:
  • Cancer
  • Urogenital
 

NICE project team

Executive Lead: TBC
Technical Lead: Nwamaka Umeweni
Communications manager: Alice Law
Project manager:

Nicole Fisher

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: (post-appeal) 8 November 2013
1st appraisal committee meeting: 13 November 2012
2nd appraisal committee meeting 13 February 2013
3rd appraisal committee meeting: 04 February 2014
Top


 

Consultees and commentators

Consultees

 

Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Pfizer (axitinib)

Patient/carer groups

  • James Whale Fund for Kidney Cancer
  • Kidney Cancer UK
  • Kidney Cancer Support Network

Professional groups

  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • NHS Central Manchester CCG
  • NHS England
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Comparator manufacturers

  • Pfizer (sunitinib)
  • GSK (pazopanib)

Relevant research groups

  • MRC Clinical Trials Unit

Evidence Review Group

  • Kleijnen Systematic Reviews Lts
  • National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated public health groups

  • none

Top


 

Project history

Date Update
4 October 2013 Following the appeal panel's decision on the appeal points heard at the appeal hearing on 10 June, this appraisal will go through the Single Technology Appraisal (STA) process again with an updated scope. The updated scope and matrix can be viewed under key documents titled post appeal.
Top


 

Key documents

This page was last updated: 03 March 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.